Valuation : Arcus Biosciences, Inc.

Market Cap 3.13B 2.7B 2.56B 2.32B 4.34B 299B 4.37B 30.25B 11.66B 152B 11.75B 11.5B 481B P/E 2026 *
-6.88x
P/E 2027 * -6.82x
Enterprise Value 2.69B 2.32B 2.2B 1.99B 3.73B 257B 3.76B 26B 10.02B 131B 10.1B 9.88B 414B EV / Sales 2026 *
34.2x
EV / Sales 2027 * 58.2x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -
1 day-5.97%
1 week-17.09%
Current month-16.02%
1 month-15.09%
3 months+3.32%
6 months+8.33%
Current year+3.19%
1 week 24.32
Extreme 24.315
29.5
1 month 24.32
Extreme 24.315
31.58
Current year 18.52
Extreme 18.515
31.74
1 year 11.3
Extreme 11.3
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 2015-04-30
Chief Executive Officer 67 2015-04-30
Director of Finance/CFO 53 2020-07-31
Director TitleAgeSince
Chairman 67 2017-11-30
Director/Board Member 65 2017-09-17
Director/Board Member 72 2015-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Controller/Auditor

8,481 0.0067%
7/10/26 Sell

Founder

-20,067 0.0160%
6/11/26 Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-5.97%-17.09%+113.45%+15.72% 3.13B
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.68B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average -0.15%-4.92%+68.48%+95.04% 26.79B
Weighted average by Cap. +0.34%-3.82%+75.05%+122.90%

Financials

2026 *2027 *
Net sales 78.61M 67.82M 64.21M 58.14M 109M 7.51B 110M 760M 293M 3.82B 295M 289M 12.09B 52.08M 44.93M 42.54M 38.52M 72.22M 4.98B 72.75M 503M 194M 2.53B 196M 191M 8.01B
Net income -451M -389M -368M -334M -625M -43.09B -630M -4.36B -1.68B -21.9B -1.69B -1.66B -69.33B -451M -389M -369M -334M -626M -43.11B -630M -4.36B -1.68B -21.92B -1.69B -1.66B -69.38B
Net Debt -441M -380M -360M -326M -611M -42.1B -616M -4.26B -1.64B -21.4B -1.65B -1.62B -67.74B -102M -88.14M -83.45M -75.56M -142M -9.76B -143M -987M -381M -4.96B -384M -375M -15.71B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
26-09-11 US$24.59 -5.97% 4,277,165
26-09-10 US$26.15 -8.21% 2,391,099
26-09-09 US$28.49 -1.96% 1,828,274
26-09-08 US$29.06 -2.02% 1,363,509
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
24.59USD
Average target price
38.75USD
Spread / Average Target
+57.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!